DIHYDROQUINAZOLINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
1 . A compound of Formula I:
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein:
R 1 is selected from the group consisting of:
(i) hydrogen,
(ii) unsubstituted or substituted C 1 -C 6 alkyl, wherein one or more substituents are independently selected from the group consisting of:
(a) unsubstituted or substituted C 6 -C 10 aryl, wherein one or more substituents are independently selected from the group consisting of:
(1) halogen,
(2) cyano,
(3) C 1 -C 6 alkyl,
(4) C 3 -C 6 cycloalkyl,
(5) C 1 -C 6 haloalkyl,
(6) —OZ 1 ,
(7) C 2 -C 6 alkenyl, and
(8) C 2 -C 6 alkynyl,
(b) unsubstituted or substituted C 3 -C 6 cycloalkyl, wherein one or more substituents are independently selected from the group consisting of:
(1) halogen,
(2) cyano,
(3) C 1 -C 6 alkyl,
(4) C 3 -C 6 cycloalkyl,
(5) C 1 -C 6 haloalkyl, and
(6) —OZ 1 ,
(c) C 2 -C 6 alkynyl,
(iii) unsubstituted or substituted C 6 -C 10 aryl, wherein one or more substituents are independently selected from the group consisting of:
(a) halogen,
(b) cyano,
(c) C 1 -C 6 alkyl,
(d) C 3 -C 6 cycloalkyl,
(e) C 1 -C 6 haloalkyl,
(f) —OZ 1 , and
(g) unsubstituted or substituted C 6 -C 10 aryl, wherein one or more substituents are independently selected from the group consisting of halogen, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, and —OZ 1 ,
(iv) unsubstituted or substituted 5- to 9-membered heteroaryl, wherein one or more substituents are independently selected from the group consisting of:
(a) halogen,
(b) cyano,
(c) C 1 -C 6 alkyl,
(d) C 3 -C 6 cycloalkyl,
(e) C 1 -C 6 haloalkyl,
(f) —OZ 1 , and
(g) unsubstituted or substituted C 6 -C 10 aryl, wherein one or more substituents are independently selected from the group consisting of halogen, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, and —OZ 1 ,
(v) unsubstituted or substituted C 3 -C 6 cycloalkyl, wherein one or more substituents are independently selected from the group consisting of:
(a) halogen,
(b) cyano,
(c) C 1 -C 6 alkyl,
(d) C 3 -C 6 cycloalkyl,
(e) C 1 -C 6 haloalkyl, and
(f) —OZ 1 ,
(vi) unsubstituted or substituted C 3 -C 6 heterocycle, wherein one or more substituents are independently selected from the group consisting of:
(a) halogen,
(b) cyano,
(c) C 1 -C 6 alkyl,
(d) C 3 -C 6 cycloalkyl,
(e) C 1 -C 6 haloalkyl, and
(f) —OZ 1 ,
(vii) —S(═O) 2 Z 2 , and
(viii) —C(═O)Z 2 ;
R 2 and R 3 are independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
Y 1 is selected from the group consisting of —CR 4a R 4b — and —NR 5 —;
R 4a is —NR 6a R 6b ;
R 4b is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
R 5 is selected from the group consisting of:
(i) hydrogen
(ii) unsubstituted or substituted C 1 -C 6 alkyl, wherein one or more substituents are independently selected from the group consisting of:
(a) cyano,
(b) hydroxy,
(c) —OZ 1 ,
(d) —C(═O)OH
(e) —C(═O)Z 2
(f) —C(═O)OZ 2 ,
(g) —C(═O)NZ 3 Z 4 ,
(h) —S(═O) 2 Z 2 ,
(i) —S(═O) 2 NZ 3 Z 4 ,
(j) —S(═O)(═NZ 5 )Z 2 ,
(k) —S(═NZ 5 )(═NZ 6 )Z 2 , and
(l) —S(═O)(═NZ 5 )NZ 3 Z 4 ,
(iii) C 1 -C 6 haloalkyl; and
(iv) unsubstituted or substituted C 2 -C 6 alkenyl, wherein one or more substituents are independently selected from the group consisting of halogen, —NZ 3 Z 4 , 4- to 8-membered heterocycle,
R 6a is selected from the group consisting of:
(i) —C(═O)Z 2
(ii) —C(═O)OZ 2 ,
(iii) —C(═O)NZ 3 Z 4 ,
(iv) —S(═O) 2 Z 2 ,
(v) —S(═O) 2 NZ 3 Z 4 ,
(vi) —S(═O)(═NZ 5 )Z 2 ,
(vii) —S(═NZ 5 )(═NZ 6 )Z 2 , and
(viii) —S(═O)(═NZ 5 )NZ 3 Z 4 ,
R 6b is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
each Z 1 is independently selected from the group consisting of:
(i) hydrogen,
(ii) C 1 -C 6 alkyl,
(iii) unsubstituted or substituted C 2 -C 6 alkenyl, wherein one or more substituents are independently selected from the group consisting of cyano, —S(═O) 2 Z 2 , —S(═O) 2 NZ 3 Z 4 , halogen, —NZ 3 Z 4 , 4- to 8-membered heterocycle,
(iv) C 2 -C 6 alkynyl,
(v) C 3 -C 6 cycloalkyl,
(vi) C 3 -C 6 cycloalkenyl, and
(vii) C 1 -C 6 haloalkyl;
each Z 2 is independently selected from the group consisting of:
(i) unsubstituted or substituted C 1 -C 6 alkyl, wherein one or more substituents are independently selected from the group consisting of cyano and C 2 -C 6 alkynyl;
(ii) unsubstituted or substituted C 2 -C 6 alkenyl, wherein one or more substituents are independently selected from the group consisting of cyano, —S(═O) 2 Z 2 , —S(═O) 2 NZ 3 Z 4 , halogen, —NZ 3 Z 4 , 4- to 8-membered heterocycle,
(iii) C 2 -C 6 alkynyl,
(iv) C 3 -C 6 cycloalkyl,
(v) C 3 -C 6 cycloalkenyl,
(vi) C 1 -C 6 haloalkyl,
(vii) unsubstituted or substituted C 6 -C 10 aryl, wherein one or more substituents are independently selected from the group consisting of halogen, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, and —OZ 1 , and
(viii) unsubstituted or substituted C 3 -C 6 cycloalkyl, wherein one or more substituents are independently selected from the group consisting of halogen, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, and —OZ 1 ;
each Z 3 and Z 4 are independently selected from the group consisting of:
(i) hydrogen;
(ii) unsubstituted or substituted C 1 -C 6 alkyl, wherein one or more substituents are independently selected from the group consisting of:
(a) unsubstituted or substituted C 6 -C 10 aryl, wherein one or more substituents are independently selected from the group consisting of:
(1) halogen,
(2) cyano,
(3) C 1 -C 6 alkyl,
(4) C 3 -C 6 cycloalkyl,
(5) C 1 -C 6 haloalkyl,
(6) —OZ 1 ,
(7) C 2 -C 6 alkenyl, and
(8) C 2 -C 6 alkynyl,
(b) unsubstituted or substituted C 3 -C 6 cycloalkyl, wherein one or more substituents are independently selected from the group consisting of:
(1) halogen,
(2) cyano,
(3) C 1 -C 6 alkyl,
(4) C 3 -C 6 cycloalkyl,
(5) C 1 -C 6 haloalkyl, and
(6) —OZ 1 ,
(c) unsubstituted or substituted 5- to 9-membered heteroaryl, wherein one or more substituents are independently selected from the group consisting of:
(1) halogen,
(2) cyano,
(3) C 1 -C 6 alkyl,
(4) C 3 -C 6 cycloalkyl,
(5) C 1 -C 6 haloalkyl,
(6) —OZ 1 ,
(7) C 2 -C 6 alkenyl, and
(8) C 2 -C 6 alkynyl,
(iii) unsubstituted or substituted C 2 -C 6 alkenyl, wherein one or more substituents are independently selected from the group consisting of cyano, —S(═O) 2 Z 2 , —S(═O) 2 NZ 3 Z 4 , halogen, —NZ 3 Z 4 , 4- to 8-membered heterocycle,
(iv) C 2 -C 6 alkynyl,
(v) C 3 -C 6 cycloalkyl,
(vi) C 3 -C 6 cycloalkenyl, and
(vii) C 1 -C 6 haloalkyl;
each Z 5 and Z 6 are independently selected from the group consisting of:
(i) hydrogen,
(ii) C 1 -C 6 alkyl, and
(iii) C 3 -C 6 cycloalkyl;
X is selected from the group consisting of —CR 7a ═ and —N═;
X 1 is selected from the group consisting of —CR 7b ═ and —N═;
X 2 is selected from the group consisting of —CR 7c ═ and —N═;
X 3 is selected from the group consisting of —CR 7d ═ and —N═; and
each R 7a , R 7b , R 7c , and R 7d is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, and —OZ 1 .
2 . The compound of claim 1 of Formula II:
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.
3 . The compound of claim 1 , or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein R 5 is unsubstituted or substituted C 1 -C 6 alkyl, wherein one substituent is selected from the group consisting of hydroxy, —C(═O)OH, and —C(═O)NZ 3 Z 4 .
4 . The compound of claim 1 of Formula III:
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.
5 . The compound of claim 1 , or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein:
R 6a is selected from the group consisting of —C(═O)Z 2 and unsubstituted or substituted C 1 -C 6 alkyl; and
Z 2 is selected from the group consisting of:
(i) C 1 -C 6 alkyl; and
(ii) unsubstituted or substituted C 2 -C 6 alkenyl, wherein one or more substituents are independently selected from the group consisting of cyano, —S(═O) 2 Z 2 , —S(═O) 2 NZ 3 Z 4 , halogen, —NZ 3 Z 4 , 4- to 8-membered heterocycle.
6 . The compound of claim 1 , or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein R 1 is unsubstituted or substituted C 6 -C 10 aryl, wherein one or more substituents are independently selected from the group consisting of halogen, hydroxy, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, and —OZ 1 .
7 . The compound of claim 1 , or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein:
X is —CR 7a ═;
X 1 is —CR 7b ═;
X 2 is —CR 7c ═; and
X 3 is —CR 7d ═.
8 . The compound of claim 1 , or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, selected from the group consisting of:
1-(4-(trifluoromethyl)phenyl)-2,3-dihydroquinazolin-4(1H)-one;
3-(3-hydroxypropyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydroquinazolin-4(1H)-one;
2-(4-oxo-1-(4-(trifluoromethyl)phenyl)-1,4-dihydroquinazolin-3(2H)-yl)acetic acid;
3-(2-hydroxyethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydroquinazolin-4(1H)-one;
2-(4-oxo-1-(4-(trifluoromethyl)phenyl)-1,4-dihydroquinazolin-3(2H)-yl)acetamide;
N-methyl-2-(4-oxo-1-(4-(trifluoromethyl)phenyl)-1,4-dihydroquinazolin-3(2H)-yl)acetamide; and
N-(4-oxo-1-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)acrylamide.
9 . A pharmaceutical composition comprising the compound of claim 1 , or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, and a pharmaceutically acceptable carrier.
10 - 14 . (canceled)
15 . A method for the prevention or treatment of a YAP/TAZ-TEAD activation mediated disorders in an animal, mammal or human comprising administering to said animal, mammal or human in need for such prevention or treatment an effective dose of the compound of claim 1 .
16 . A method of treatment or prevention of YAP/TAZ-TEAD activation mediated disorder according to claim 15 to a patient in need thereof in combination with one or more other medicines selected from the group consisting of EGFR inhibitors, MEK inhibitors, AXL inhibitors, B-RAF inhibitors, and RAS inhibitors.